CHARLOTTE, N.C. and STAMFORD, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company, is pleased to announce that in an ...

Most people with HCM can participate in mild- to moderate-intensity exercise safely. When it comes to vigorous exercise and competitive sports, there may be a need for additional guidance from your ...

MINNEAPOLIS — Readouts of data on an experimental drug for hypertrophic cardiomyopathies showed the agent appeared safe and effective in long-term treatment and can significantly improve exercise ...

CHARLOTTE, N.C. & STAMFORD, Conn.--(BUSINESS WIRE)--HCM II Acquisition Corp. (Nasdaq: HOND) (“HCM II”), a special-purpose acquisition company and Terrestrial ...

CHARLOTTE, N.C. & STAMFORD, Conn., September 29, 2025--(BUSINESS WIRE)--HCM II Acquisition Corp. (Nasdaq: HOND) ("HCM II"), a special-purpose acquisition company and ...

Oracle yesterday announced more than a dozen AI agents that will be available as part of its Fusion HCM application, complementing the twelve already announced earlier this year, along with many ...

Oracle Corp. today announced a series of new agentic artificial intelligence extensions to its Fusion Cloud Human Capital Management suite, bringing the number of agents in the application to more ...

MADRID, Spain—For patients with hypertrophic cardiomyopathy (HCM), research presented today at the European Society of Cardiology (ESC) Congress 2025 demonstrated both the promise and the potential ...

Panel A shows a cross-section of a normal heart (top) and an endomyocardial biopsy sample from a normal heart (bottom; with hematoxylin and eosin staining) that shows normal histologic characteristics ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...